Registry update — unassessed
PhActHealth - Physical Activity and Healthy Aging: Fighting Low Grade Chronic Inflammation to Put Out the Cardio-oncologic Risk
Trial registry update: RECRUITING. No results reported in the supplied registry record.
RCTMinor significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Aug 20, 2026 · Discovered: Sep 18, 2026 · Assessed: — · Research update
What it does not prove
- No results are reported—this is a protocol description, not outcome data, so effectiveness of the exercise intervention cannot be evaluated.
- The study does not address whether exercise affects cancer prognosis, recurrence, or survival.
- Without reported effect sizes or sample size justification, the statistical power and clinical meaningfulness of any findings remain unknown.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Women with newly diagnosed luminal B or triple-negative breast cancer who are candidates for neoadjuvant therapy.
- Primary outcome
- Improvement in exercise capacity
- Effect size
- —
- Significance
- Not reported
- Journal
- University of Milan
- Published
- Aug 20, 2026
Sources
Primary source
- University of Milan ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
PhActHealth is a multicenter randomized controlled trial enrolling women with newly diagnosed luminal B or triple-negative breast cancer (BC) who are candidates for neoadjuvant therapy.
Participants are randomly assigned to either an intervention group or a control group.
All patients receive lifestyle counseling, while those in the intervention group additionally follow a personalized aerobic and resistance exercise program throughout the neoadjuvant treatment period before surgery.
The primary outcome is the improvement in exercise capacity.
The secondary outcomes are tumor-specific and systemic responses to the intervention, evaluated by analyzing molecular, metabolic, and inflammatory markers, as well as clinical and functional parameters.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.